Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction

Ken Sugimoto, Hiroshi Itoh, Katsuomi Iwakura, Masashi Ikushima, Akinobu Kato, Ryusuke Kimura, Koji Tanaka, Tohru Masuyama, Toshio Ogihara, Shigeo Kawano, Kenshi Fujii

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

The aim of this retrospective study was to assess whether intravenous nicorandil, a hybrid of NO and a KATP channel opener, in conjunction with percutaneous coronary intervention (PCI) improves the long-term prognosis in patients with acute myocardial infarction (AMI). Intravenous nicorandil has already been shown to improve the in-hospital prognosis of patients with anterior AMI. The study population consisted of 272 patients with a reperfused AMI who were admitted during a similar time interval, before (control; n= 114) and after nicorandil treatment (n=158). In the nicorandil group, a 4 mg bolus injection was given, followed by 6 mg/h infusion for 24 h and then oral nicorandil at 15 mg/day for at least 1 month. In the patients with an anterior AMI, left ventricular (LV) function was better and the frequency of LV remodeling was lower after 3 months in the nicorandil group; however, in those with a non-anterior AMI, there were no differences in functional outcome and the frequency of LV remodeling between the 2 groups. The frequency of cardiac events was significantly lower in the nicorandil group, and the use of nicorandil was derived as a potential factor related to freedom from cardiac events (p

Original languageEnglish
Pages (from-to)295-300
Number of pages6
JournalCirculation Journal
Volume67
Issue number4
Publication statusPublished - Apr 1 2003
Externally publishedYes

Fingerprint

Nicorandil
Myocardial Reperfusion
Myocardial Infarction
Ventricular Remodeling
Therapeutics
KATP Channels
Percutaneous Coronary Intervention
Left Ventricular Function
Retrospective Studies
Injections

Keywords

  • Contrast agent
  • Echocardiography
  • Microcirculation
  • Myocardial infarction
  • Reperfusion
  • Ventricular function

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology

Cite this

Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction. / Sugimoto, Ken; Itoh, Hiroshi; Iwakura, Katsuomi; Ikushima, Masashi; Kato, Akinobu; Kimura, Ryusuke; Tanaka, Koji; Masuyama, Tohru; Ogihara, Toshio; Kawano, Shigeo; Fujii, Kenshi.

In: Circulation Journal, Vol. 67, No. 4, 01.04.2003, p. 295-300.

Research output: Contribution to journalArticle

Sugimoto, K, Itoh, H, Iwakura, K, Ikushima, M, Kato, A, Kimura, R, Tanaka, K, Masuyama, T, Ogihara, T, Kawano, S & Fujii, K 2003, 'Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction', Circulation Journal, vol. 67, no. 4, pp. 295-300.
Sugimoto, Ken ; Itoh, Hiroshi ; Iwakura, Katsuomi ; Ikushima, Masashi ; Kato, Akinobu ; Kimura, Ryusuke ; Tanaka, Koji ; Masuyama, Tohru ; Ogihara, Toshio ; Kawano, Shigeo ; Fujii, Kenshi. / Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction. In: Circulation Journal. 2003 ; Vol. 67, No. 4. pp. 295-300.
@article{91902f4f63e643709dfd5ff76fab4278,
title = "Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction",
abstract = "The aim of this retrospective study was to assess whether intravenous nicorandil, a hybrid of NO and a KATP channel opener, in conjunction with percutaneous coronary intervention (PCI) improves the long-term prognosis in patients with acute myocardial infarction (AMI). Intravenous nicorandil has already been shown to improve the in-hospital prognosis of patients with anterior AMI. The study population consisted of 272 patients with a reperfused AMI who were admitted during a similar time interval, before (control; n= 114) and after nicorandil treatment (n=158). In the nicorandil group, a 4 mg bolus injection was given, followed by 6 mg/h infusion for 24 h and then oral nicorandil at 15 mg/day for at least 1 month. In the patients with an anterior AMI, left ventricular (LV) function was better and the frequency of LV remodeling was lower after 3 months in the nicorandil group; however, in those with a non-anterior AMI, there were no differences in functional outcome and the frequency of LV remodeling between the 2 groups. The frequency of cardiac events was significantly lower in the nicorandil group, and the use of nicorandil was derived as a potential factor related to freedom from cardiac events (p",
keywords = "Contrast agent, Echocardiography, Microcirculation, Myocardial infarction, Reperfusion, Ventricular function",
author = "Ken Sugimoto and Hiroshi Itoh and Katsuomi Iwakura and Masashi Ikushima and Akinobu Kato and Ryusuke Kimura and Koji Tanaka and Tohru Masuyama and Toshio Ogihara and Shigeo Kawano and Kenshi Fujii",
year = "2003",
month = "4",
day = "1",
language = "English",
volume = "67",
pages = "295--300",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "4",

}

TY - JOUR

T1 - Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction

AU - Sugimoto, Ken

AU - Itoh, Hiroshi

AU - Iwakura, Katsuomi

AU - Ikushima, Masashi

AU - Kato, Akinobu

AU - Kimura, Ryusuke

AU - Tanaka, Koji

AU - Masuyama, Tohru

AU - Ogihara, Toshio

AU - Kawano, Shigeo

AU - Fujii, Kenshi

PY - 2003/4/1

Y1 - 2003/4/1

N2 - The aim of this retrospective study was to assess whether intravenous nicorandil, a hybrid of NO and a KATP channel opener, in conjunction with percutaneous coronary intervention (PCI) improves the long-term prognosis in patients with acute myocardial infarction (AMI). Intravenous nicorandil has already been shown to improve the in-hospital prognosis of patients with anterior AMI. The study population consisted of 272 patients with a reperfused AMI who were admitted during a similar time interval, before (control; n= 114) and after nicorandil treatment (n=158). In the nicorandil group, a 4 mg bolus injection was given, followed by 6 mg/h infusion for 24 h and then oral nicorandil at 15 mg/day for at least 1 month. In the patients with an anterior AMI, left ventricular (LV) function was better and the frequency of LV remodeling was lower after 3 months in the nicorandil group; however, in those with a non-anterior AMI, there were no differences in functional outcome and the frequency of LV remodeling between the 2 groups. The frequency of cardiac events was significantly lower in the nicorandil group, and the use of nicorandil was derived as a potential factor related to freedom from cardiac events (p

AB - The aim of this retrospective study was to assess whether intravenous nicorandil, a hybrid of NO and a KATP channel opener, in conjunction with percutaneous coronary intervention (PCI) improves the long-term prognosis in patients with acute myocardial infarction (AMI). Intravenous nicorandil has already been shown to improve the in-hospital prognosis of patients with anterior AMI. The study population consisted of 272 patients with a reperfused AMI who were admitted during a similar time interval, before (control; n= 114) and after nicorandil treatment (n=158). In the nicorandil group, a 4 mg bolus injection was given, followed by 6 mg/h infusion for 24 h and then oral nicorandil at 15 mg/day for at least 1 month. In the patients with an anterior AMI, left ventricular (LV) function was better and the frequency of LV remodeling was lower after 3 months in the nicorandil group; however, in those with a non-anterior AMI, there were no differences in functional outcome and the frequency of LV remodeling between the 2 groups. The frequency of cardiac events was significantly lower in the nicorandil group, and the use of nicorandil was derived as a potential factor related to freedom from cardiac events (p

KW - Contrast agent

KW - Echocardiography

KW - Microcirculation

KW - Myocardial infarction

KW - Reperfusion

KW - Ventricular function

UR - http://www.scopus.com/inward/record.url?scp=0037390281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037390281&partnerID=8YFLogxK

M3 - Article

VL - 67

SP - 295

EP - 300

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 4

ER -